Clinical trial NCT02354170 - References

Central Serous Chorioretinopathy — Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

Citation(s)

•   Avci R, Deutman AF
  [Treatment of central serous choroidopathy with the beta receptor blocker metoprolol (preliminary results)]. Klin Monbl Augenheilkd. 1993 Mar;202(3):199-205. German.
•   Bouzas EA, Karadimas P, Pournaras CJ
  Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002 Sep-Oct;47(5):431-48. Review.
•   Bujarborua D
  Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand. 2001 Aug;79(4):417-21.
•   Castro-Correia J, Coutinho MF, Rosas V, Maia J
  Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992;81(4):379-86.
•   Chan WM, Lai TY, Lai RY, Liu DT, Lam DS
  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct;115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5.
•   Davis KL, Nappi JM
  The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther. 2003 Nov;25(11):2647-68. Review.
•   Ficker L, Vafidis G, While A, Leaver P
  Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988 Nov;72(11):829-34.
•   Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E
  Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003 Apr 2;41(7):1148-55.
•   Folk JC, Thompson HS, Han DP, Brown CK
  Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. 1984 Sep;102(9):1299-302.
•   Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB
  Finasteride for chronic central serous chorioretinopathy. Retina. 2011 Apr;31(4):766-71. doi: 10.1097/IAE.0b013e3181f04a35.
•   Fujimoto H, Gomi F, Wakabayashi T, Sawa M, Tsujikawa M, Tano Y
  Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology. 2008 Sep;115(9):1494-500, 1500.e1-2. doi: 10.1016/j.ophtha.2008.01.021. Epub 2008 Apr 18.
•   Gemenetzi M, De Salvo G, Lotery AJ
  Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010 Dec;24(12):1743-56. doi: 10.1038/eye.2010.130. Epub 2010 Oct 8. Review.
•   Gilbert CM, Owens SL, Smith PD, Fine SL
  Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984 Nov;68(11):815-20.
•   Golshahi A, Klingmüller D, Holz FG, Eter N
  Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010 Aug;88(5):576-81. doi: 10.1111/j.1755-3768.2008.01467.x. Epub 2009 May 12.
•   Imamura Y, Fujiwara T, Margolis R, Spaide RF
  Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009 Nov-Dec;29(10):1469-73. doi: 10.1097/IAE.0b013e3181be0a83.
•   Inoue R, Sawa M, Tsujikawa M, Gomi F
  Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol. 2010 Mar;149(3):441-6.e1-2. doi: 10.1016/j.ajo.2009.10.011.
•   Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K
  Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002 Aug;40(2):117-23.
•   Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF
  Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010 Sep;117(9):1792-9. doi: 10.1016/j.ophtha.2010.01.023. Epub 2010 May 15.
•   McCurley A, Jaffe IZ
  Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012 Mar 24;350(2):256-65. doi: 10.1016/j.mce.2011.06.014. Epub 2011 Jun 24. Review.
•   Montero JA, Ruiz-Moreno JM
  Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2005 May;89(5):562-4.
•   Nielsen JS, Jampol LM
  Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011 Oct;31(9):1928-36. doi: 10.1097/IAE.0b013e31821c3ef6.
•   Pikkel J, Beiran I, Ophir A, Miller B
  Acetazolamide for central serous retinopathy. Ophthalmology. 2002 Sep;109(9):1723-5.
•   Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.
•   Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F
  Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6.
•   Robertson DM, Ilstrup D
  Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr;95(4):457-66.
•   Ross A, Ross AH, Mohamed Q
  Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2011 May;22(3):166-73. doi: 10.1097/ICU.0b013e3283459826. Review.
•   Shin JY, Woo SJ, Yu HG, Park KH
  Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011 Jan;31(1):119-26. doi: 10.1097/IAE.0b013e3181e378f2.
•   Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA
  Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996 Dec;103(12):2070-9; discussion 2079-80.
•   Spitznas M, Huke J
  Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol. 1987;225(6):437-40.
•   Taban M, Boyer DS, Thomas EL, Taban M
  Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004 Jun;137(6):1073-80.
•   Tatham A, Macfarlane A
  The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006 Apr;22(2):145-9.
•   Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA
  Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999 Jul;128(1):63-8.
•   Weinberger MH, Roniker B, Krause SL, Weiss RJ
  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 Aug;15(8):709-16.
•   Yannuzzi LA
  Type-A behavior and central serous chorioretinopathy. Retina. 1987 Summer;7(2):111-31. Review.
•   Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F
  Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012 Jul;122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11.

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)

Details for clinical trial NCT02354170